The world of HIV and disease, and some new approaches to block it.
Gallo
R
R
Institute for Human Virology, University of Maryland, Baltimore, USA.
D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D018946:Chemokine CCL5 / Q000627:therapeutic use; D018925:Chemokines / Q000627:therapeutic use; D019049:Developed Countries / Q000706:statistics & numerical data; D003906:Developing Countries / Q000706:statistics & numerical data; D004196:Disease Outbreaks / Q000517:prevention & control; D000077560:Enfuvirtide; D015696:Gene Products, tat / Q000037:antagonists & inhibitors; D014943:Global Health; D006678:HIV / Q000187:drug effects / Q000502:physiology*; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D016898:Interferon-alpha / Q000037:antagonists & inhibitors; D010446:Peptide Fragments / Q000494:pharmacology; D015728:Receptors, HIV / Q000037:antagonists & inhibitors; D014779:Virus Replication; D054322:tat Gene Products, Human Immunodeficiency Virus
D019380:Anti-HIV Agents; D018946:Chemokine CCL5; D018925:Chemokines; D015696:Gene Products, tat; D015700:HIV Envelope Protein gp41; D016898:Interferon-alpha; D010446:Peptide Fragments; D015728:Receptors, HIV; D054322:tat Gene Products, Human Immunodeficiency Virus; D000077560:Enfuvirtide